Moderna, Inc. (MRNA) saw its stock price surge 5.04% during intraday trading on Wednesday.
The sharp rise follows reports that a key U.S. federal vaccine advisory panel has abandoned a push to potentially stop recommending mRNA COVID-19 vaccines. The panel, under Health and Human Services Secretary Robert F. Kennedy Jr., is no longer moving forward with the plan, according to the Washington Post.
This development removes a significant regulatory overhang for Moderna, a leading producer of mRNA vaccines. The news suggests continued institutional support for the technology, which is central to the company's business model.